IMBiotechnologies Treats First Patient in Enlarged Prostate Study of OCL 500 Embolization Safety and Efficacy
News
IMBiotechnologies Ltd. has announced the treatment of the first patient in its clinical study to evaluate the safety and efficacy of OCL500, an agent for prostate artery embolization to treat benign prostate hypertrophy (BPH). Dr. ... Read more